We believe that having invested and dedicated leadership begins with a management team that encourages innovation and creative thought processes amongst employees.
Our management team encompasses a diverse background of experience and credentials that support and enhance our company’s goals.
The board of directors understands our company and takes the time to conduct thorough reviews and ask challenging questions in a continual effort to increase long-term shareholder value.
Gerald (Gerry) D. Sakowski
Chief Executive Officer
Gerry Sakowski joined CMP Pharma in July 2013. Sakowski brings 25 years of experience working within contract services and generic drug development and commercialization. Previous positions include staff scientist at Oneida Research Services, Whitesboro, NY, and Analytical Business Manager at Applied Analytical Industries (AAI), Wilmington, NC. From 1997-2013, Sakowski held positions with Metrics, Inc. as Director of Marketing and Sales, Vice President of Business Development, Sr. Vice President and COO, and most recently, Executive Vice President of Commercial Operations. He earned his Bachelor of Science degrees in biology and chemistry from Evangel University in Springfield, Missouri.
Chief Financial Officer
Pat Raimer joined CMP Pharma in April 2017. Raimer brings over 20 years of financial experience including 12 years in the pharma industry. Previous positions include Interim CFO, and Director of FP&A at Qualitest Pharmaceuticals and Business Unit Controller at KV Pharmaceutical. He has a Bachelors of Science in Accounting from the University of Illinois, Certified Public Accountant.
John Dilda joined CMP Pharma in 1986. Dilda brings 30 years of pharmaceutical manufacturing experience and earned an Associate degree in Applied Science.
Director of Quality Assurance
Melanie Little Joined CMP Pharma in February 2017. Little brings 20 years of related pharmaceutical quality experience to the team. Previous positions include QA Specialist, QA Supervisor, Principal Quality Associate, Regulatory Compliance Audit Support for DSM Pharmaceuticals, Metrics, Inc. and Mayne Pharma, Inc. Melanie has an Associates of Applied Science in Biotechnology from Pitt Community College.
Director of Product Development
Anthony Pipho joined CMP Pharma in August 2014. Pipho brings 15 years of experience working in pharmaceutical development and drug formulation. Previous positions included Development Scientist, Lab Supervisor and Senior Analytical Chemist for Metrics, Inc. He has a Bachelor of Science degree in biochemistry from East Carolina University.
Board of Directors
Steve Cagle is the Chairman of the Board of CMP Pharma. Previously, Mr. Cagle served as CEO of Moberg Pharma North America (formerly Alterna LLC) and prior to that was a principal management team member of Sparta Systems, where he served in various sales, marketing, and operational roles. Mr. Cagle also serves on the Board of Directors at M2S. Mr. Cagle received a Bachelor of Science from Rutgers and a Master of Business Administration from NYU Stern School of Business.
Henry Smith is the founder of CMP Pharma and has been a pioneer in the development of FDA-approved oral suspensions and topical products. Before founding the company, Mr. Smith was a professor at the School of Pharmacy at the University of North Carolina Chapel Hill. Mr. Smith received a Bachelor of Science from Campbell University and a Bachelor of Science from the University of North Carolina at Chapel Hill.
Mr. Aitken-Davies is a co-founder of Altaris. Prior to the formation of Altaris, he held various positions in Merrill Lynch’s private equity and healthcare investment banking groups. Mr. Aitken-Davies received a Masters in Biochemistry from the University of Oxford and investigated the metabolism of bovine prion protein for his research dissertation at the Università di Padova, Italy. Mr. Aitken-Davies currently serves on the Board of Overseers of the Children’s Hospital of Philadelphia and as a board member of the Senator Foundation.
Dr. Robert “Rob” Watson
Dr. Watson is a principal at Altaris. Prior to joining Altaris, he was a member of the healthcare team at Hg Capital and Ares Life Sciences, where he executed a number of buyout and growth capital investments in various healthcare sectors. Dr. Watson also previously worked at Sofinnova Partners in Paris.
Bruce Friedman is a retired pharmaceutical executive and consultant. He has more than 40 years of experience in the pharmaceutical and diagnostic industries, most recently as Vice President, Technical Operations at Noven Pharmaceuticals. Mr. Friedman was a founder of JDS Pharmaceuticals, a specialty pharmaceutical company acquired by Noven Pharmaceuticals in 2007. Previous companies include Pfizer, Carter-Wallace and MedPointe. Mr. Friedman has both a Bachelor of Science and a Master of Science from Columbia University.